Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial
<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....
Uloženo v:
| Hlavní autor: | |
|---|---|
| Další autoři: | , , , , , , , , , |
| Vydáno: |
2025
|
| Témata: | |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
